{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:23:55Z","timestamp":1792873435905,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jneuroim.2026.579044","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:19:14Z","timestamp":1785453554000},"page":"579044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Identification of PTGS2 as a genetically supported protective biomarker and potential therapeutic target in myasthenia gravis"],"prefix":"10.1016","volume":"420","author":[{"given":"Yuwei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jneuroim.2026.579044_bb0005","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s13287-025-04534-9","article-title":"Mesenchymal stromal cells conditioned by peripheral blood mononuclear cells exert enhanced immunomodulation capacities and alleviate a model of myasthenia gravis","volume":"16","author":"Bayer","year":"2025","journal-title":"Stem Cell Res. Ther."},{"issue":"7","key":"10.1016\/j.jneuroim.2026.579044_bb0010","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10654-015-0011-z","article-title":"Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors","volume":"30","author":"Burgess","year":"2015","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.jneuroim.2026.579044_bb0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579044_bb0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer Immunogenomic analyses reveal genotype-Immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.jneuroim.2026.579044_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.763538","article-title":"Relationship between serum amino acid levels and bone mineral density: a Mendelian randomization study","volume":"12","author":"Cui","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"9","key":"10.1016\/j.jneuroim.2026.579044_bb0030","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/014107680710000923","article-title":"Capitalizing on Mendelian randomization to assess the effects of treatments","volume":"100","author":"Davey Smith","year":"2007","journal-title":"J. R. Soc. Med."},{"key":"10.1016\/j.jneuroim.2026.579044_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.641013","article-title":"Frontiers of autoantibodies in autoimmune disorders: crosstalk between Tfh\/Tfr and regulatory B cells","volume":"12","author":"Ding","year":"2021","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.jneuroim.2026.579044_bb0040","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1096\/fasebj.12.12.1063","article-title":"Cyclooxygenase in biology and disease","volume":"12","author":"Dubois","year":"1998","journal-title":"FASEB J."},{"key":"10.1016\/j.jneuroim.2026.579044_bb0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jneuroim.2026.579044_bb0050","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34408","article-title":"The MR-base platform supports systematic causal inference across the human phenome","volume":"7","author":"Hemani","year":"2018","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.jneuroim.2026.579044_bb0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.jneuroim.2026.579044_bb0060","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3233\/JND-180300","article-title":"Efficacy of rituximab in refractory generalized anti-AChR myasthenia gravis","volume":"5","author":"Landon-Cardinal","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579044_bb0065","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12967-024-04994-2","article-title":"Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"issue":"14","key":"10.1016\/j.jneuroim.2026.579044_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e34364","article-title":"Weighted gene coexpression network analysis and machine learning for the determination of tfh cell and B cell infiltrating biomarkers in thymoma-associated myasthenia gravis","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"issue":"8","key":"10.1016\/j.jneuroim.2026.579044_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70436","article-title":"Single-cell atlas reveals heterogeneous response to FcRn blockade in anti-AChR antibody-positive generalised myasthenia gravis","volume":"15","author":"Li","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.jneuroim.2026.579044_bb0085","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaut.2017.05.005","article-title":"Methylome and transcriptome profiling in myasthenia gravis monozygotic twins","volume":"82","author":"Mamrut","year":"2017","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579044_bb0090","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s43141-023-00568-9","article-title":"Mutational screening of GDAP1 in dysphonia associated with Charcot-Marie-tooth disease: clinical insights and phenotypic effects","volume":"21","author":"Manzoor","year":"2023","journal-title":"J. Genet. Eng. Biotechnol."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579044_bb0100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2026.579044_bb0105","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for Management of Myasthenia Gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jneuroim.2026.579044_bb0110","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.it.2016.12.001","article-title":"Single-cell genomics: approaches and utility in immunology","volume":"38","author":"Neu","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jneuroim.2026.579044_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.916934","article-title":"Differentiation of T helper 17 cells may mediate the abnormal humoral immunity in IgA nephropathy and inflammatory bowel disease based on shared genetic effects","volume":"13","author":"Qing","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579044_bb0120","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"7","key":"10.1016\/j.jneuroim.2026.579044_bb0125","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jneuroim.2026.579044_bb0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2026.579044_bb0135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2005.09.001","article-title":"Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients","volume":"170","author":"Saito","year":"2005","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579044_bb0140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nbt.3192","article-title":"Spatial reconstruction of single-cell gene expression data","volume":"33","author":"Satija","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.jneuroim.2026.579044_bb0145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J. Clin. Neuromuscul. Dis."},{"issue":"3","key":"10.1016\/j.jneuroim.2026.579044_bb0150","doi-asserted-by":"crossref","first-page":"314","DOI":"10.21037\/jtd.2016.03.03","article-title":"Increased frequency of thymic T follicular helper cells in myasthenia gravis patients with thymoma","volume":"8","author":"Song","year":"2016","journal-title":"J. Thorac. Dis."},{"issue":"2","key":"10.1016\/j.jneuroim.2026.579044_bb0155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"issue":"6 Suppl 1","key":"10.1016\/j.jneuroim.2026.579044_bb0160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0049-0172(97)80046-7","article-title":"Mechanism of action of aspirin-like drugs","volume":"26","author":"Vane","year":"1997","journal-title":"Semin. Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579044_bb0165","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"issue":"7","key":"10.1016\/j.jneuroim.2026.579044_bb0170","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579044_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100097","article-title":"Integrative single-cell RNA sequencing and mendelian randomization analysis reveal the potential role of synaptic vesicle cycling-related genes in Alzheimer's disease","volume":"12","author":"Zeng","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579044_bb0180","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12035-014-8985-1","article-title":"Intrathymic Tfh\/B cells interaction leads to ectopic GCs formation and anti-AChR antibody production: central role in triggering MG occurrence","volume":"53","author":"Zhang","year":"2016","journal-title":"Mol. Neurobiol."},{"issue":"10","key":"10.1016\/j.jneuroim.2026.579044_bb0185","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41588-020-0682-6","article-title":"Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases","volume":"52","author":"Zheng","year":"2020","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579044_bb0190","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12967-023-04421-y","article-title":"Peripheral immune landscape for hypercytokinemia in myasthenic crisis utilizing single-cell transcriptomics","volume":"21","author":"Zhong","year":"2023","journal-title":"J. Transl. Med."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826001931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826001931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:24:48Z","timestamp":1788873888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572826001931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":36,"alternative-id":["S0165572826001931"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579044","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of PTGS2 as a genetically supported protective biomarker and potential therapeutic target in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"579044"}}